Crispr Therapeutics AG (CRSP)
Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)
Curing disease, as opposed to just masking symptoms, is a big deal. CRISPR Therapeutics aims to cure by editing problem genes. So CRSP is the future of medicine! This approach can be too futuristic for many tastes. That, plus questions about CRSP's ability to scale production and make treatments affordable, have been like a cloud over the stock. But in June, CRSP picked up some big-time expressions of support from Washington (including new HHS Secretary RFK Jr.). The stock responded with a strong rally.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51.19, representing a -1.88% change from its previous close.
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day.
The Big 3: CRSP, OKLO, GME
Mike Shorr (@ProsperTradingAcademy) looks to manage risk levels in his 3 example options trades. For Crispr Therapeutics (CRSP), he's looking at low-implied volatility in the gene-editing biotech company.
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line.
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
